PURE — Pure Biosciences Share Price
0.000.00%
Last trade - 00:00- $11.92m
- $16.27m
- $1.96m
- 22
- 16
- 59
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3100% | ||
| Return on Equity | n/a | ||
| Operating Margin | -137.81% | ||
Financial Summary
| Year End 31st Jul | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.92 | 3.93 | 1.85 | 1.88 | 1.96 | n/a | n/a | 0.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PURE Bioscience, Inc. is a creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial. The Company is focused on developing and commercializing its proprietary antimicrobial products, primarily in the food and beverage industry. It provides solutions to combat the health and environmental challenges of pathogens and hygienic control. Its technology platform is based on patented, stabilized ionic silver, and its initial products contain SDC. Its registered offerings include PURE Hard Surface, a food contact surface sanitizer and disinfectant designed for restaurant chains, food processors, and transportation companies, as well as PURE Control, a direct food contact processing aid. It also supplies SDC-based formulations as raw material ingredients for personal care products. Its SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, the United States Food and Drug Administration, and Health Canada.
Directors
- Tom Lee CHM (72)
- Mark Elliott CFO (46)
- Tom Myers COO (69)
- Jason Kawata VPR
- Ivan Chen IND (39)
- David Rendall IND (48)
- Kristin Taylor IND (53)
- Last Annual
- July 31st, 2024
- Last Interim
- April 30th, 2025
- Incorporated
- February 28th, 2011
- Public Since
- August 8th, 1996
- No. of Shareholders
- 219
- No. of Employees
- 11
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 111,886,473
- Address
- 771 Jamacha Road #512, EL CAJON, 92019
- Web
- https://www.purebio.com/
- Phone
- +1 6195968600
- Contact
- Mark Elliott
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for PURE
Q1 2026 PURE Biosciences Inc Earnings Release
Similar to PURE
Adapti
Pink Sheets on Nasdaq
All American Gold
Pink Sheets on Nasdaq
American Education Center
Pink Sheets on Nasdaq
Arem Pacific
Pink Sheets on Nasdaq
Axia International
Pink Sheets on Nasdaq
FAQ
What is the Pure Biosciences share price?
As of Today at 22:47 UTC, shares in Pure Biosciences are trading at $0.11. This share price information is delayed by 15 minutes.
How has the Pure Biosciences share price performed this year?
Shares in Pure Biosciences last closed at $0.11 and the price had moved by +74.59% over the past 365 days. In terms of relative price strength the Pure Biosciences share price has outperformed the S&P500 Index by +54.17% over the past year.
What are the analyst and broker recommendations for Pure Biosciences?
There is no consensus recommendation for this security.
Find out moreWhat is the Pure Biosciences dividend yield?
Pure Biosciences does not currently pay a dividend.
Does Pure Biosciences pay a dividend?
Pure Biosciences does not currently pay a dividend.
When does Pure Biosciences next pay dividends?
Pure Biosciences does not currently pay a dividend.
How do I buy Pure Biosciences shares?
To buy shares in Pure Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pure Biosciences?
As of the previous close price of $0.11, shares in Pure Biosciences had a market capitalisation of $11.92m.
Where are Pure Biosciences shares listed?
Here are the trading details for Pure Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PURE
What kind of share is Pure Biosciences?
Based on an overall assessment of its quality, value and momentum Pure Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pure Biosciences share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Pure Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pure Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +59.17%.
As of the last closing price of $0.11, shares in Pure Biosciences were trading +37.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pure Biosciences PE Ratio?
The Pure Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pure Biosciences?
Pure Biosciences' management team is headed by:
- Tom Lee - CHM
- Mark Elliott - CFO
- Tom Myers - COO
- Jason Kawata - VPR
- Ivan Chen - IND
- David Rendall - IND
- Kristin Taylor - IND